Research Highlight: Study on COVID‑19 in Children With Neuromuscular Disorders
Study from the Neuromuscular Working Group of the Spanish Pediatric Neurology Society
The NMD4C would like to highlight a paper from the Neuromuscular Working Group of the Spanish Pediatric Neurology Society, who have recently published a study which aims to describe the clinical characteristics and outcome of COVID-19 in the pediatric NMD patient population.
The most prevalent NMD in the study were SMA type 1 and 2 (including patients undergoing treatment with nusinersen, risdiplam or salbutamol), and Duchenne Muscular Dystrophy (including patients undergoing treatment with deflazacort), along with several other neuromuscular conditions.
Although derived from a small sample size, the study’s conclusions suggest that the course of COVID-19 in pediatric NMD populations may not be as severe as expected, due to the mitigating role of young age compared to risk factors including decreased respiratory capacity or a weak cough.
The NMD4C hopes to see further studies published which examine the impact of the COVID-19 virus across both adult and pediatric NMD populations to further our knowledge of its impact within our community.
Read the full article here
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.